Is OTLK or AURA more profitable?

Oncobiologics' return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -291.28% Aura Biosciences N/A -78.12% -64.08%

Is ALLO or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Oncobiologics N/A N/A -291.28%

Is OTLK or CLYM more profitable?

Oncobiologics' return on equity of 0.00% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -291.28% Climb Bio N/A -31.45% -30.39%

Does the media prefer OTLK or CLYM?

In the previous week, Climb Bio had 1 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Climb Bio and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.67 beat Climb Bio's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Climb Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, OCS or OTLK?

Oncobiologics has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 462.24 -$119.44M -$2.13 N/A Oncobiologics $1.35M 174.28 -$62.42M -$1.17 N/A

Is OCS or OTLK more profitable?

Oncobiologics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oncobiologics' return on equity of 0.00% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% Oncobiologics N/A N/A -291.28%

Does the media favor OCS or OTLK?

In the previous week, Oculis had 1 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Oculis and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.67 beat Oculis' score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncobiologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OTLK or CADL more profitable?

Oncobiologics' return on equity of 0.00% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -291.28% Candel Therapeutics N/A -60.42% -41.33%

Does the media prefer OTLK or CADL?

In the previous week, Candel Therapeutics had 1 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Candel Therapeutics and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.67 beat Candel Therapeutics' score of 0.00 indicating that Oncobiologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Oncobiologics (OTLK) Competitors

$1.68 -0.02 (-1.18%)

Closing price 04:00 PM Eastern

Extended Trading

$1.68 0.00 (-0.18%)

As of 08:00 PM Eastern

Compare

OTLK vs. AURA, ALLO, CLYM, OCS, and CADL

Should you buy Oncobiologics stock or one of its competitors? MarketBeat compares Oncobiologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncobiologics include Aura Biosciences (AURA), Allogene Therapeutics (ALLO), Climb Bio (CLYM), Oculis (OCS), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry.

How does Oncobiologics compare to Aura Biosciences?

Oncobiologics (NASDAQ:OTLK) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Oncobiologics has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	174.28	-$62.42M	-$1.17	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Oncobiologics presently has a consensus price target of $6.50, suggesting a potential upside of 286.90%. Aura Biosciences has a consensus price target of $20.50, suggesting a potential upside of 191.19%. Given Oncobiologics' higher probable upside, research analysts clearly believe Oncobiologics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Oncobiologics' return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
Aura Biosciences	N/A	-78.12%	-64.08%

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 1.8% of Oncobiologics shares are held by company insiders. Comparatively, 6.3% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Oncobiologics has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

In the previous week, Oncobiologics had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 1 mentions for Oncobiologics and 0 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.94 beat Oncobiologics' score of 0.67 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncobiologics	Positive
Aura Biosciences	Positive

Summary

Oncobiologics beats Aura Biosciences on 8 of the 14 factors compared between the two stocks.

How does Oncobiologics compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by insiders. Comparatively, 1.8% of Oncobiologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Oncobiologics had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 1 mentions for Oncobiologics and 0 mentions for Allogene Therapeutics. Oncobiologics' average media sentiment score of 0.67 beat Allogene Therapeutics' score of -1.74 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Allogene Therapeutics	Very Negative
Oncobiologics	Positive

Allogene Therapeutics currently has a consensus target price of $8.52, suggesting a potential upside of 315.72%. Oncobiologics has a consensus target price of $6.50, suggesting a potential upside of 286.90%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Allogene Therapeutics is more favorable than Oncobiologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Allogene Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Oncobiologics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	35,377.88	-$190.89M	-$0.77	N/A
Oncobiologics	$1.35M	174.28	-$62.42M	-$1.17	N/A

Oncobiologics' return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Oncobiologics	N/A	N/A	-291.28%

Summary

Allogene Therapeutics beats Oncobiologics on 9 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Climb Bio?

Oncobiologics (NASDAQ:OTLK) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

Oncobiologics' return on equity of 0.00% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
Climb Bio	N/A	-31.45%	-30.39%

Oncobiologics presently has a consensus price target of $6.50, suggesting a potential upside of 286.90%. Climb Bio has a consensus price target of $21.73, suggesting a potential upside of 70.41%. Given Oncobiologics' higher probable upside, equities analysts clearly believe Oncobiologics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

Climb Bio has lower revenue, but higher earnings than Oncobiologics. Climb Bio is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	174.28	-$62.42M	-$1.17	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

In the previous week, Climb Bio had 1 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Climb Bio and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.67 beat Climb Bio's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 2.6% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Oncobiologics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

Summary

Climb Bio beats Oncobiologics on 9 of the 15 factors compared between the two stocks.

How does Oncobiologics compare to Oculis?

Oculis (NASDAQ:OCS) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Oncobiologics has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	462.24	-$119.44M	-$2.13	N/A
Oncobiologics	$1.35M	174.28	-$62.42M	-$1.17	N/A

In the previous week, Oculis had 1 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Oculis and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.67 beat Oculis' score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncobiologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

22.3% of Oculis shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Oculis presently has a consensus target price of $38.33, suggesting a potential upside of 231.60%. Oncobiologics has a consensus target price of $6.50, suggesting a potential upside of 286.90%. Given Oncobiologics' higher probable upside, analysts plainly believe Oncobiologics is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oculis has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Oncobiologics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oncobiologics' return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Oncobiologics	N/A	N/A	-291.28%

Summary

Oncobiologics beats Oculis on 9 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Candel Therapeutics?

Oncobiologics (NASDAQ:OTLK) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Candel Therapeutics has lower revenue, but higher earnings than Oncobiologics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	174.28	-$62.42M	-$1.17	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Oncobiologics' return on equity of 0.00% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
Candel Therapeutics	N/A	-60.42%	-41.33%

Oncobiologics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.49, indicating that its share price is 149% less volatile than the broader market.

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Oncobiologics presently has a consensus price target of $6.50, suggesting a potential upside of 286.90%. Candel Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 94.17%. Given Oncobiologics' higher possible upside, equities research analysts plainly believe Oncobiologics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Candel Therapeutics had 1 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Candel Therapeutics and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.67 beat Candel Therapeutics' score of 0.00 indicating that Oncobiologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Candel Therapeutics beats Oncobiologics on 8 of the 14 factors compared between the two stocks.

Get Oncobiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OTLK vs. The Competition

Export

Metric	Oncobiologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$238.08M	$3.49B	$6.54B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-1.44	11.34	21.43	22.01
Price / Sales	174.28	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	-2.80	8.26	10.76	6.41
Net Income	-$62.42M	$23.91M	$3.56B	$337.14M
7 Day Performance	1.82%	3.05%	1.37%	-0.48%
1 Month Performance	442.11%	2.40%	0.81%	0.49%
1 Year Performance	-5.08%	56.35%	30.53%	28.16%

Oncobiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OTLK Oncobiologics	3.5944 of 5 stars	$1.68 -1.2%	$6.50 +286.9%	+1.2%	$238.08M	$1.35M	N/A	20	Gap Up
AURA Aura Biosciences	2.9344 of 5 stars	$6.45 +0.6%	$20.50 +217.8%	+14.1%	$662.71M	N/A	N/A	50
ALLO Allogene Therapeutics	2.357 of 5 stars	$1.94 +2.1%	$8.52 +339.3%	+69.7%	$655.79M	$20K	N/A	310
CLYM Climb Bio	3.2011 of 5 stars	$11.49 +0.4%	$21.73 +89.1%	+925.0%	$655.09M	N/A	N/A	9	Analyst Forecast
OCS Oculis	2.8447 of 5 stars	$11.61 +4.7%	$38.33 +230.2%	-40.4%	$643.05M	$1.45M	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OTLK) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncobiologics (OTLK) Competitors

OTLK vs. AURA, ALLO, CLYM, OCS, and CADL

How does Oncobiologics compare to Aura Biosciences?

Summary

How does Oncobiologics compare to Allogene Therapeutics?

Summary

How does Oncobiologics compare to Climb Bio?

Summary

How does Oncobiologics compare to Oculis?

Summary

How does Oncobiologics compare to Candel Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncobiologics (OTLK) Competitors

OTLK vs. AURA, ALLO, CLYM, OCS, and CADL

How does Oncobiologics compare to Aura Biosciences?

Which has higher earnings & valuation, OTLK or AURA?

Do analysts prefer OTLK or AURA?

Is OTLK or AURA more profitable?

Do institutionals and insiders have more ownership in OTLK or AURA?

Which has more volatility and risk, OTLK or AURA?

Does the media refer more to OTLK or AURA?

Summary

How does Oncobiologics compare to Allogene Therapeutics?

Do insiders and institutionals have more ownership in ALLO or OTLK?

Does the media refer more to ALLO or OTLK?

Do analysts recommend ALLO or OTLK?

Which has more risk and volatility, ALLO or OTLK?

Which has higher valuation and earnings, ALLO or OTLK?

Is ALLO or OTLK more profitable?

Summary

How does Oncobiologics compare to Climb Bio?

Is OTLK or CLYM more profitable?

Do analysts prefer OTLK or CLYM?

Which has stronger earnings and valuation, OTLK or CLYM?

Does the media prefer OTLK or CLYM?

Do insiders & institutionals have more ownership in OTLK or CLYM?

Which has more volatility & risk, OTLK or CLYM?

Summary

How does Oncobiologics compare to Oculis?

Which has higher earnings and valuation, OCS or OTLK?

Does the media favor OCS or OTLK?

Do institutionals and insiders hold more shares of OCS or OTLK?

Do analysts recommend OCS or OTLK?

Which has more risk & volatility, OCS or OTLK?

Is OCS or OTLK more profitable?

Summary

How does Oncobiologics compare to Candel Therapeutics?

Which has higher earnings & valuation, OTLK or CADL?

Is OTLK or CADL more profitable?

Which has more risk & volatility, OTLK or CADL?

Do institutionals & insiders hold more shares of OTLK or CADL?

Do analysts rate OTLK or CADL?

Does the media prefer OTLK or CADL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools